NCT03708627EARLY_PHASE1Recruiting

Bimatoprost as a Treatment for Graves' Orbitopathy

Johns Hopkins University

Start Date

11/1/2017

Completion Date

7/1/2031

Summary

Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: Graves' Ophthalmopathy with Exophthalmos/Proptosis - Exclusion Criteria: Active Graves Disease, Currently pregnant, Taking Steroids \-

Interventions

DRUG

Bimatoprost Ophthalmic

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Graves Ophthalmopathy

Locations

University of Washington

Seattle, Washington 98104

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.